Pipeline Programs & Milestones - RP-3467 (Polθ ATPase inhibitor) is in Phase 1/2 trials with initial POLAR topline data expected in Q3 2025[9, 25, 71] - RP-1664 (PLK4 inhibitor) is in Phase 1/2 trials with initial LIONS topline data expected in Q4 2025[9, 41, 71] - Lunresertib/Camonsertib (PKMYT1/ATR inhibitors) completed Lunre+WEE1i enrollment in Q2 2025[9, 71] RP-3467 (Polθ ATPase Inhibitor) - RP-3467 targets a global market segment addressable at over $16 billion across PARP inhibitors, RLT, and chemotherapy combinations[12] - Preclinical data shows deep/durable complete responses with PARPi combination, representing a ~$3 billion global market segment[14] - Preclinical data shows survival benefit in unselected tumor backgrounds, representing a ~$8 billion global market segment[14] - Preclinical data shows RP-3467 is well-tolerated with carboplatin/irinotecan, representing a ~$5 billion global market segment[14] RP-1664 (PLK4 Inhibitor) - RP-1664 targets a ~63,000 addressable patient population with TRIM37-high tumors, with initial focus on pediatric neuroblastoma (>80% TRIM37-high)[28] Lunresertib + Camonsertib - Lunre+camo achieved POC in 2L EC and 3L PROC with nearly half of patients maintaining PFS at 24 weeks[44] - In efficacy-evaluable patients with EC or PROC at RP2D, 73% of patients had tumor shrinkage and 31% (16/51) response rate[47] - In PROC patients with alterations, 75% experienced tumor shrinkage with 37.5% ORR (conf.+ unconf.) and 16.7% ORR (conf.)[54] - The progression-free rate at 24 weeks was 43% (95% CI: 21-63%) in EC patients and 45% (95% CI: 22-66%) in PROC patients[52, 58] Financial Status - The company has $124 million in cash and investments as of March 31, 2025, providing runway through 2027[8, 71]